Literature DB >> 15897496

Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up.

M Capecci1, R A Ricciuti, D Burini, V G Bombace, L Provinciali, M Iacoangeli, M Scerrati, M G Ceravolo.   

Abstract

OBJECTIVE: This study aimed to assess the effectiveness of chronic bilateral STN-S in improving the functional status of PD patients compared with patients treated with drugs alone.
METHODS: Controlled study of disability index changes over 12 and 24 month chronic STN stimulation. Of 39 patients with advanced PD meeting CAPSIT criteria for STN-S, 23 underwent surgery; 16 patients decided against surgery and continued on drug schedule adjustments. Functional status was measured using the Activities of Daily Living section of the Unified Parkinson's Disease Rating Scale (UPDRS-ADL), Brown's Disability Scale, and Functional Independence Measure. UPDRS motor score and subscores for selected items, levodopa equivalent daily dose, and Beck Depression Inventory scores were also monitored.
RESULTS: T12 follow up data were available for all 39 patients and T24 data for 13 STN-S and 8 control subjects. Compared with controls, STN-S patients experienced significant or highly significant improvements in all independence measures at both 12 and 24 months (time x treatment effect T12: F = 19.5, p = 0.00008; T24: F = 6.2, p = 0.005). Forward stepwise regression for independent predictors of the yearly rate of UPDRS-ADL score modification in the entire sample showed that treatment was the only factor significantly associated with functional status change (beta coefficient -0.54, t value -2.5, p = 0.02), whereas other variables-UPDRS motor score, BDI, and age at disease onset and enrolment-were not in the equation.
CONCLUSION: STN-S is an effective therapeutic option in advanced PD. It induced a consistent improvement of functional abilities over two years to an extent that was not achieved with drug therapy alone.

Entities:  

Mesh:

Year:  2005        PMID: 15897496      PMCID: PMC1739649          DOI: 10.1136/jnnp.2004.047001

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  48 in total

1.  Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.

Authors:  M C Rodriguez-Oroz; I Zamarbide; J Guridi; M R Palmero; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

2.  Mood changes with deep brain stimulation of STN and GPi: results of a pilot study.

Authors:  M S Okun; J Green; R Saben; R Gross; K D Foote; J L Vitek
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-11       Impact factor: 10.154

3.  Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group.

Authors:  J Jankovic; M McDermott; J Carter; S Gauthier; C Goetz; L Golbe; S Huber; W Koller; C Olanow; I Shoulson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

4.  Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study.

Authors:  O Bratfos; J O Haug
Journal:  Acta Psychiatr Scand       Date:  1979-07       Impact factor: 6.392

5.  Assessment of depression: the depression inventory.

Authors:  A T Beck; A Beamesderfer
Journal:  Mod Probl Pharmacopsychiatry       Date:  1974

6.  The Functional Independence Measure: a comparative validity and reliability study.

Authors:  D Kidd; G Stewart; J Baldry; J Johnson; D Rossiter; A Petruckevitch; A J Thompson
Journal:  Disabil Rehabil       Date:  1995-01       Impact factor: 3.033

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up.

Authors:  B Ford; L Winfield; S L Pullman; S J Frucht; Y Du; P Greene; J H Cheringal; Q Yu; L J Cote; S Fahn; G M McKhann; R R Goodman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

9.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Authors:  Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

10.  Accuracy of self-reported disability in patients with parkinsonism.

Authors:  R G Brown; B MacCarthy; M Jahanshahi; C D Marsden
Journal:  Arch Neurol       Date:  1989-09
View more
  4 in total

1.  STN DBS of Advanced Parkinson's Disease Experienced in a Specialized Monitoring Unit with a Prospective Protocol.

Authors:  Ji Yeoun Lee; Jung Ho Han; Han Joon Kim; Beom Seok Jeon; Dong Gyu Kim; Sun Ha Paek
Journal:  J Korean Neurosurg Soc       Date:  2008-07-20

2.  Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.

Authors:  Hélène Gervais-Bernard; Jing Xie-Brustolin; Patrick Mertens; Gustavo Polo; Hélène Klinger; Dario Adamec; Emmanuel Broussolle; Stéphane Thobois
Journal:  J Neurol       Date:  2009-02-26       Impact factor: 4.849

3.  Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up.

Authors:  Jing Gan; Jing Xie-Brustolin; Patrick Mertens; Gustavo Polo; Hélène Klinger; Hélène Mollion; Isabelle Benatru; Emmanuel Henry; Emmanuel Broussolle; Stéphane Thobois
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

Review 4.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.